Pfizer Strategy Shake-Up: Andrew Baum to Exit After Transitioning to Advisor Role
Pfizer
New Delhi: Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according to an analyst note on Monday.
Baum, who joined Pfizer in 2024, will transition into the role of senior strategic advisor to CEO Albert Bourla before fully exiting the company by the end of this year, according to a BMO Capital Markets note.
The drugmaker and Baum were not immediately available for comment when contacted by Reuters.
"This move is likely reflective of continued operational simplification at the company rather than a major strategic shift," BMO analysts said.
Baum was a long-time analyst at Citi (C.N), opens new tab, where he served as head of global healthcare and managing director of equity research, before joining Pfizer. Prior to his role at Citi, Baum covered European pharmaceuticals at Morgan Stanley (MS.N), opens new tab.
He will still be involved in helping manage the company's higher-level strategy but less involved in the day-to-day operations, the note said.
